Novartis

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica ...
Novartis

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed ...
Novartis

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...
Novartis

Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech

Imagine stepping into a space where cutting-edge technology meets life-changing impact. At Novartis we’re building something extraordinary – an Innovation Lab (iLab) where we are mastering the art and ...
Novartis

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...
Novartis

Supercharging R&D: How AI helps us to bring medicines to patients faster

Max leads AI innovation in pharmaceutical development at Novartis. His story reflects how cutting-edge technology is combined with human expertise for meaningful impact. “I didn’t set out to work in ...
Novartis

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as ...
Novartis

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types Company broke ground on 4 new manufacturing and R&D facilities, ...
Novartis

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...
Novartis

Novartis AG has informed the Board of Novartis India Limited “NIL” that Novartis AG has entered into an agreement with ChrysCapital, one of India’s largest private equity ...

February 19, 2026 – Novartis AG has notified the Board of Novartis India Limited (“NIL”), a company listed on BSE Limited, that Novartis AG has entered into an agreement with the ChrysCapital group ...
Novartis

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...
Novartis

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company ...